论文部分内容阅读
为评价青光眼减压阀引流术治疗新生血管性青光眼，在视网膜血管性疾病、糖尿病、眼外伤所致的新生血管性青光眼２９例２９眼施行青光眼减压阀引流术，植入Ａｈｍｅｄ减压阀２０眼，Ｋｒｕｐｉｎ减压阀９眼。青光眼控制标准为６ｍｍＨｇ≤眼压≤２１ｍｍＨｇ，视功能保持或有所改善。结果：手术总成功率７５．８６％，眼压从术前平均５２．５６±１４．５１ｍｍＨｇ下降到２０．１５±１３．２６ｍｍＨｇ，平均随访１７．８３个月。有７眼在眼压正常后虹膜新生血管完全消退。术后３个月成功率７９．３１％，６个月成功率７６．１９％，１年成功率６６．６７％。主要手术并发症有前房导管口阻塞１３．７９％，浅前房１０．３４％，前房出血３．４５％。结论：青光眼减压阀引流术治疗新生血管性青光眼获得较为满意的疗效，是目前值得推荐的治疗选择。
In order to evaluate the efficacy of glaucoma drainage in the treatment of neovascular glaucoma, 29 patients with 29 eyes with neovascular glaucoma caused by retinal vascular diseases, diabetes mellitus and ocular trauma were treated with glaucoma decompression valve drainage and implantation of Ahmed pressure reducing valve 20 Eye, Krupin valve 9 eyes. Glaucoma control standard 6mmHg ≤ IOP ≤ 21mmHg, visual function to maintain or improve. Results: The operative total success rate was 75.86%. The intraocular pressure decreased from 52.56 ± 14.51 mmHg to 20.15 ± 13.26 mmHg, with an average follow-up of 17.83 months. There are 7 eyes in the normal iris neovascularization subsided. The success rate of 3 months after operation was 79.31%, the success rate of 6 months was 76.19%, and the success rate of 1 year was 66.67%. The main complications were anterior chamber catheter obstruction 13.79%, shallow anterior chamber 10.34%, 3.45% anterior chamber hemorrhage. Conclusion: Glaucoma decompression valve drainage for the treatment of neovascular glaucoma to obtain a more satisfactory curative effect is the recommended treatment option.